Enzon Pharmaceuticals Stock Cash Flow From Operations
| ENZNDelisted Stock | USD 0.20 0.01 5.26% |
Enzon Pharmaceuticals fundamentals help investors to digest information that contributes to Enzon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Enzon OTC Stock. The fundamental analysis module provides a way to measure Enzon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzon Pharmaceuticals otc stock.
Enzon |
Enzon Pharmaceuticals OTC Stock Cash Flow From Operations Analysis
Enzon Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Enzon Pharmaceuticals Cash Flow From Operations | (501 K) |
Most of Enzon Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Enzon Pharmaceuticals has (501,000) in Cash Flow From Operations. This is 100.1% lower than that of the Biotechnology sector and 100.8% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.05% higher than that of the company.
Enzon Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzon Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Enzon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enzon Pharmaceuticals by comparing valuation metrics of similar companies.Enzon Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Enzon Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | -0.0138 | ||||
| Operating Margin | (36.28) % | ||||
| Current Valuation | 17.63 M | ||||
| Shares Outstanding | 74.21 M | ||||
| Shares Owned By Insiders | 10.70 % | ||||
| Shares Owned By Institutions | 48.58 % | ||||
| Number Of Shares Shorted | 259.38 K | ||||
| Price To Earning | 1.52 X | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 669.36 X | ||||
| Revenue | 701 K | ||||
| Gross Profit | 701 K | ||||
| EBITDA | (469 K) | ||||
| Net Income | (469 K) | ||||
| Cash And Equivalents | 46.79 M | ||||
| Cash Per Share | 0.63 X | ||||
| Debt To Equity | 1.46 % | ||||
| Current Ratio | 125.26 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (501 K) | ||||
| Short Ratio | 1.71 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 14.0 | ||||
| Beta | 0.17 | ||||
| Market Capitalization | 19.72 M | ||||
| Total Asset | 47.75 M | ||||
| Retained Earnings | (75.61 M) | ||||
| Working Capital | 6.98 M | ||||
| Current Asset | 11.78 M | ||||
| Current Liabilities | 4.8 M | ||||
| Z Score | -1.4 | ||||
| Annual Yield | 0.65 % | ||||
| Net Asset | 47.75 M |
About Enzon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enzon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Enzon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enzon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enzon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Enzon OTC Stock
The ability to find closely correlated positions to Enzon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enzon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enzon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enzon Pharmaceuticals to buy it.
The correlation of Enzon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enzon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enzon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enzon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in nation. Note that the Enzon Pharmaceuticals information on this page should be used as a complementary analysis to other Enzon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Enzon OTC Stock
If you are still planning to invest in Enzon Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enzon Pharmaceuticals' history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |